Approaches to Cardiovascular Disease and Its Treatment

Diabetes Care

Volumn 26, Issue 12, 2003, Pages 3342-3348

  Bloomgarden, Zachary T ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GEMFIBROZIL; INSULIN; LOSARTAN; METFORMIN; RAMIPRIL; SIBUTRAMINE; SULFONYLUREA; TETRAHYDROLIPSTATIN;

CARDIOVASCULAR DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY BLOOD FLOW; DIETARY INTAKE; DISEASE ASSOCIATION; DRUG EFFICACY; FUNCTION TEST; HEART FUNCTION; HUMAN; HYPERTENSION; IMAGING SYSTEM; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HEART ARREST; HUMANS; METABOLIC SYNDROME X;

EID: 0344412845     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.12.3342     Document Type: Review

References (21)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434-444, 1993
2. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). BMJ 316:823-828, 1998
3. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, Clegg LX: Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 146:483-494, 1997
4. del Sol AI, Moons KG, Hollander M, Hofman A, Koudstaal PJ, Grobbee DE, Breteler MM, Witteman JC, Bots ML: Is carotid intima-media thickness useful in cardiovascular disease risk assessment? The Rotterdam Study. Stroke 32:1532-1535, 2001
5. Mack WJ, Selzer RH, Hodis HN, Erickson JK, Liu CR, Liu CH, Crawford DW, Blankenhorn DH: One-year reduction and longitudinal analysis of carotid intima-media thickness associated with colestipol/niacin therapy. Stroke 24:1779-1783, 1993
6. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN: ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 106:2055-2060, 2002
7. Wagenknecht LE, D'Agostino RB Jr, Haffner SM, Savage PJ, Rewers M: Impaired glucose tolerance, type 2 diabetes, and carotid wall thickness: the Insulin Resistance Atherosclerosis Study. Diabetes Care 21:1812-1818, 1998
8. Dubuisson JT, Wagenknecht LE, D'Agostino RB Jr, Haffner SM, Rewers M, Saad MF, Laws A, Herrington DM: Association of hormone replacement therapy and carotid wall thickness in women with and without diabetes. Diabetes Care 21:1790-1796, 1998
9. Maser RE, Mitchell BD, Vinik AI, Freeman R: The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 26:1895-1901, 2003
10. Whitsel EA, Boyko EJ, Siscovick DS: Re-assessing the role of QTc in the diagnosis of autonomic failure among patients with diabetes: a meta-analysis. Diabetes Care 23:241-247, 2000
11. The Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
12. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, the National Heart, Lung, and Blood Institute joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, the National High Blood Pressure Education Program Coordinating Committee: The Seventh Report of the joint National Committee on. Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289:2560-2572, 2003
13. NIH conference Consensus Development Conference Panel.: Gastrointestinal surgery for severe obesity. Ann Intern Med 115:956-961, 1991
14. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J: Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension 38:E28-E32, 2001
15. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, the RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
16. Collins R, Armitage J, Parish S, Sleigh P, Peto R, the Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005-2016, 2003
17. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341:410-418, 1999
18. Robins Sj: Targeting low high-density lipoprotein cholesterol for therapy: lessons from the Veterans Affairs High.-density Lipoprotein Intervention Trial. Am J Cardiol 88:19N-23N, 2001
19. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393, 2003
20. Jewell M: FDA: antipsychotic drugs, diabetes linked [article online], 18 September 2003. Available at www.newsday. com. Accessed 16 October 2003
21. Kavey RE, Daniels SR, Lauer RM, Atkins DL, Hayman LL, Taubert K, the American Heart Association: American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation 107:1562-1566, 2003